Biocon Biologics Ltd (BBL), a subsidiary of Biocon Limited, has announced plans to expand its oncology portfolio with the introduction of three new biosimilar candidates. The new additions include biosimilar versions of Trastuzumab\/Hyaluronidase, Nivolumab, and Pembrolizumab, which are used to treat various types of cancer. With these new additions, Biocon Biologics will offer one of the broadest oncology biosimilar portfolios in the industry, addressing some of the world’s highest-revenue biologics that are expected to lose exclusivity over the next five years.<\/p>\n
The company’s oncology portfolio represents a market opportunity exceeding $75 billion, accounting for nearly 35% of the global oncology pharmaceutical market. Biocon Limited has also announced plans to integrate Biocon Biologics as a wholly owned subsidiary, which is expected to simplify the corporate structure, enhance global commercial leverage, and strengthen Biocon’s leadership across diabetes, oncology, and immunology.<\/p>\n
The integration, which is targeted to be completed by March 31, 2026, subject to regulatory approvals, will enable Biocon to offer biosimilar insulins alongside complex peptide generics, addressing the full continuum of diabetes care. Biocon Biologics’ CEO and Managing Director, Shreehas Tambe, commented that the integration will significantly enhance the company’s ability to deliver high-quality, affordable medicines at scale.<\/p>\n
Biocon Biologics is a fully integrated global biosimilars company that serves over 6.3 million patients across 120 countries, providing high-quality biosimilars at affordable costs. The company has commercialized 10 biosimilars to date and has a pipeline of over 20 biosimilar assets spanning various therapeutic areas. Biocon Biologics is committed to advancing environmental, social, and governance priorities aligned with the United Nations Sustainable Development Goals.<\/p>\n
The company’s expansion into the oncology market is expected to improve access to affordable cancer treatments worldwide. Biosimilars have been shown to be effective in reducing the cost of biologic treatments, making them more accessible to patients who may not have been able to afford them otherwise. With its expanded portfolio, Biocon Biologics is well-positioned to play a significant role in the global oncology market. The company’s commitment to delivering high-quality, affordable medicines is expected to have a positive impact on patients and healthcare systems worldwide.<\/p>\n","protected":false},"excerpt":{"rendered":"
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Limited, has announced plans to expand its oncology portfolio with the introduction of three new biosimilar candidates. The new additions include biosimilar versions of Trastuzumab\/Hyaluronidase, Nivolumab, and Pembrolizumab, which are used to treat various types of cancer. With these new additions, Biocon Biologics will offer one of […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","fifu_image_url":"","fifu_image_alt":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[14,2],"tags":[],"class_list":["post-89764","post","type-post","status-publish","format-standard","hentry","category-biocon","category-pharma"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":89877,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/29\/sp-global-upgrades-biocon-biologics-credit-rating-to-bb-with-a-stable-outlook-reports-indiamedtoday\/","url_meta":{"origin":89764,"position":0},"title":"S&P Global Upgrades Biocon Biologics’ Credit Rating to ‘BB+’ with a Stable Outlook, Reports IndiaMedToday","author":"Team Small News","date":"January 29, 2026","format":false,"excerpt":"S&P Global Ratings has upgraded the long-term issuer credit rating of Biocon Biologics, a subsidiary of Biocon Limited, to 'BB+' from 'BB'. The rating agency has also maintained a stable outlook for the company. This upgrade is a testament to Biocon Biologics' strong business profile, driven by its robust product\u2026","rel":"","context":"In "Biocon"","block_context":{"text":"Biocon","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/biocon\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89824,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/19\/biocon-expects-robust-q3-performance-fueled-by-biosimilar-growth\/","url_meta":{"origin":89764,"position":1},"title":"Biocon Expects Robust Q3 Performance Fueled by Biosimilar Growth","author":"Team Small News","date":"January 19, 2026","format":false,"excerpt":"Biocon, a leading biopharmaceutical company, is expected to have a strong third quarter in the fiscal year 2026 (Q3FY26). The company's biosimilars segment is anticipated to drive this growth, with key products such as bStelara playing a significant role. Analysts predict substantial revenue growth, driven by the increasing adoption of\u2026","rel":"","context":"In "Biocon"","block_context":{"text":"Biocon","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/biocon\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89869,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/27\/zydus-lifesciences-introduces-indias-first-biosimilar-version-of-nivolumab-a-global-breakthrough\/","url_meta":{"origin":89764,"position":2},"title":"Zydus Lifesciences introduces India’s first biosimilar version of Nivolumab, a global breakthrough.","author":"Team Small News","date":"January 27, 2026","format":false,"excerpt":"Zydus Lifesciences, a leading life sciences company, has launched the world's first biosimilar of nivolumab in India under the brand name Tishtha. This milestone marks a significant expansion of patient access to cutting-edge cancer therapies, particularly in the field of Immuno-Oncology. Tishtha will be available in two dosage strengths, 100\u2026","rel":"","context":"In "Pharma"","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":89898,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/02\/03\/glenmark-pharmaceuticals-sets-sights-on-fy28-for-debut-of-oncology-drugs-and-expansion-of-profit-margins-reports-etpharma\/","url_meta":{"origin":89764,"position":3},"title":"Glenmark Pharmaceuticals sets sights on FY28 for debut of oncology drugs and expansion of profit margins, reports ETPharma.","author":"Team Small News","date":"February 3, 2026","format":false,"excerpt":"Glenmark Pharmaceuticals, a leading Indian pharmaceutical company, has expressed confidence that its cancer drug, Trastuzumab Rezetecan (SHR-A1811), will enter licensed markets by FY28, driving an improvement in both gross and EBITDA margins. The company has guided for an EBITDA margin of 23% for the ongoing fiscal year and expects its\u2026","rel":"","context":"In "Glenmark"","block_context":{"text":"Glenmark","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/glenmark\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89747,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/04\/tragedy-strikes-in-bengaluru-as-26-year-old-biocon-staff-member-takes-fatal-leap-from-5th-floor-of-office-building\/","url_meta":{"origin":89764,"position":4},"title":"Tragedy strikes in Bengaluru as 26-year-old Biocon staff member takes fatal leap from 5th floor of office building.","author":"Team Small News","date":"January 4, 2026","format":false,"excerpt":"A 26-year-old employee of Biocon, a biopharmaceutical company, jumped to his death from the 5th floor of the company's office building in Bengaluru, India. The incident occurred on a recent day, and the police are currently investigating the circumstances surrounding the death. According to reports, the employee, whose identity has\u2026","rel":"","context":"In "Biocon"","block_context":{"text":"Biocon","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/biocon\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89789,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/12\/delhi-high-court-grants-permission-to-zydus-to-market-nivolumab-biosimilar-a-cancer-treatment-drug-in-india\/","url_meta":{"origin":89764,"position":5},"title":"Delhi High Court grants permission to Zydus to market Nivolumab biosimilar, a cancer treatment drug, in India.","author":"Team Small News","date":"January 12, 2026","format":false,"excerpt":"The Delhi High Court has allowed Zydus Lifesciences to sell and market its biosimilar version of the anti-cancer drug nivolumab in India, despite a patent infringement suit filed by the innovator and patent holder, E.R. Squibb & Sons LLC. The court modified a previous order that had restrained the launch\u2026","rel":"","context":"In "Pharma"","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]}],"_links":{"self":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89764","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/comments?post=89764"}],"version-history":[{"count":0,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89764\/revisions"}],"wp:attachment":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media?parent=89764"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/categories?post=89764"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/tags?post=89764"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}